Noninvasive quantification of iodine-123-iomazenil SPECT.

UNLABELLED The feasibility of a noninvasive method for quantification of [123I]iomazenil binding using a standardized arterial input function and a single venous blood sample was assessed in normal volunteers. METHODS Serial SPECT images and blood data from six healthy male volunteers after intravenous injection of [123I]iomazenil were used. The standardized input function was derived by averaging the six subjects' arterial curves. Individual input functions were estimated by calibrating the standardized input function with one-point venous blood radioactivity concentration. Ligand transport (K1) and receptor binding were computed from the estimated input functions and two separate SPECT scans using a table look-up procedure based on a three-compartment, two-parameter model. Reference values for K1 and receptor binding were determined from the serial SPECT data and individual arterial curves using a three-compartment, three-parameter model and curve fitting. RESULTS Analyses of the error caused by the calibration in relation to the time postinjection revealed that the optimal calibration time was 30 min postinjection. Receptor binding obtained by this simplified method correlated well with the reference values (r = 0.941) and was estimated within an error of 10% in the cerebral cortical regions. Although the estimated K1 showed relatively poor correlation (r = 0.699) with the reference value, it was an excellent relative measure in each subject. CONCLUSION Our method provided an absolute measure of the benzodiazepine receptor binding and a relative measure of ligand transport from two SPECT scans and a venous blood sample. This method would be useful for quantitative assessment of benzodiazepine receptors in clinical settings.

[1]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[2]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[3]  M. de Roo,et al.  Evaluation of a multicentre study with Iomazenil--a benzodiazepine receptor ligand. , 1991, Nuclear medicine communications.

[4]  D E Kuhl,et al.  Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  R. Koeppe,et al.  Parametric in vivo imaging of benzodiazepine receptor distribution in human brain , 1991, Annals of neurology.

[6]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  B. Schmitz,et al.  123-I-iomazenil-SPECT in patients with focal epilepsies--a comparative study with 99mTc-HMPAO-SPECT, CT and MR. , 1991, Advances in Experimental Medicine and Biology.

[8]  G. V. von Schulthess,et al.  123I-Iomazenil: A Quantitative Study of the Central Benzodiazepine Receptor Distribution , 1992, Nuklearmedizin.

[9]  V. Dhawan,et al.  Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. , 1993, Radiology.

[10]  Robert B. Innis,et al.  SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: I. Kinetic Modeling of Single Bolus Experiments , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  P B Hoffer,et al.  Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.